VEDOKIDS
Contact
Description
This study aims to prospectively explore the real life short and longer term outcomes of Vedolizumab in pediatric inflammatory bowel disease and to develop a prediction model for treatment success based on Vedolizumab trough levels and other clinical and laboratory markers. Children under 18 years of age that have been diagnosed with IBD and their physician is starting treatment with Vedolizumab may be eligible.
Eligibility and criteria
IRB Number:
18-015108
Eligible age range:
Clinical trial phase:
N/A
Official title:
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.